CV Sciences (CVSI) EBIT Growth (1y) (2012 - 2026)
CV Sciences (CVSI) EBIT Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 25.63% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.30% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -319.32% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -14.89% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 97.23% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 719.49% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.25% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -2,990.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,990.91% |
| Dec 31, 2025 | 88.39% |
| Sep 30, 2025 | 19.35% |
| Jun 30, 2025 | 77.53% |
| Mar 31, 2025 | 101.77% |
| Dec 31, 2024 | 27.33% |
| Sep 30, 2024 | 21.97% |
| Jun 30, 2024 | 45.82% |
| Mar 31, 2024 | -110.76% |
| Dec 31, 2023 | 58.16% |
| Sep 30, 2023 | 51.01% |
| Jun 30, 2023 | 53.52% |
| Mar 31, 2023 | 480.33% |
| Dec 31, 2022 | 75.97% |
| Sep 30, 2022 | 70.07% |
| Jun 30, 2022 | 34.05% |
| Mar 31, 2022 | 51.33% |
| Dec 31, 2021 | 6.56% |
| Sep 30, 2021 | 5.43% |
| Jun 30, 2021 | 24.63% |